Cetraxate

D-NMAPPD is an Acid Ceramidase (ceramidase) inhibitor, which acts to keep ceramide concentrations low and maintain cell viability in normal cells. The inhibition of Acid Ceramidase (ceramidase) in both non-cancerous and malignant cells leads to

D-NMAPPD is an Acid Ceramidase (ceramidase) inhibitor, which acts to keep ceramide concentrations low and maintain cell viability in normal cells. The inhibition of Acid Ceramidase (ceramidase) in both non-cancerous and malignant cells leads to

D-NMAPPD is an Acid Ceramidase (ceramidase) inhibitor, which acts to keep ceramide concentrations low and maintain cell viability in normal cells. The inhibition of Acid Ceramidase (ceramidase) in both non-cancerous and malignant cells leads to

D-NMAPPD is an Acid Ceramidase (ceramidase) inhibitor, which acts to keep ceramide concentrations low and maintain cell viability in normal cells. The inhibition of Acid Ceramidase (ceramidase) in both non-cancerous and malignant cells leads to

A potent ceramidase inhibitor that induces apoptosis in human colorectal cancer, keratinocyte, and melanoma cell lines produces approximately 50% cell non-viability at 10 &microM and &gt80% cell death at 100 &microM.

A potent ceramidase inhibitor that induces apoptosis in human colorectal cancer, keratinocyte, and melanoma cell lines produces approximately 50% cell non-viability at 10 &microM and &gt80% cell death at 100 &microM.

A potent ceramidase inhibitor that induces apoptosis in human colorectal cancer, keratinocyte, and melanoma cell lines produces approximately 50% cell non-viability at 10 &microM and &gt80% cell death at 100 &microM.

E6130 is an orally active and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.In VitroE6130 is an orally active and highly selective CX3CR1 modulator, inhibits the fractalkine-induced chemotaxis

E6130 is an orally active and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.In VitroE6130 is an orally active and highly selective CX3CR1 modulator, inhibits the fractalkine-induced chemotaxis

E6130 is an orally active and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.In VitroE6130 is an orally active and highly selective CX3CR1 modulator, inhibits the fractalkine-induced chemotaxis

E6130 is an orally active and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.In VitroE6130 is an orally active and highly selective CX3CR1 modulator, inhibits the fractalkine-induced chemotaxis

E6130 is an orally active and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.In VitroE6130 is an orally active and highly selective CX3CR1 modulator, inhibits the fractalkine-induced chemotaxis